MCID: ZKF001
MIFTS: 41

Zika Fever

Categories: Blood diseases, Infectious diseases, Neuronal diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Zika Fever

MalaCards integrated aliases for Zika Fever:

Name: Zika Fever 12 52 15
Zika Virus Infection 52 58 3 43 71
Zika Virus Disease 12 52 58
Zika Virus 74 42

Characteristics:

Orphanet epidemiological data:

58
zika virus disease
Inheritance: Not applicable; Prevalence: 1-5/10000 (Brazil); Age of onset: All ages; Age of death: adult;

Classifications:

Orphanet: 58  
Rare infectious diseases


External Ids:

Disease Ontology 12 DOID:0060478
MeSH 43 D000071243
ICD10 32 A92.8
ICD10 via Orphanet 33 U06
Orphanet 58 ORPHA448237
UMLS 71 C0276289

Summaries for Zika Fever

MedlinePlus : 42 Zika is a virus that is spread mostly by mosquitoes. A pregnant mother can pass it to her baby during pregnancy or around the time of birth. It can spread through sexual contact. There have also been reports that the virus has spread through blood transfusions. There have been outbreaks of Zika virus in the United States, Africa, Southeast Asia, the Pacific Islands, parts of the Caribbean, and Central and South America. Most people who get the virus do not get sick. One in five people do get symptoms, which can include a fever, rash, joint pain, and conjunctivitis (pinkeye). Symptoms are usually mild, and start 2 to 7 days after being bitten by an infected mosquito. A blood test can tell whether you have the infection. There are no vaccines or medicines to treat it. Drinking lots of fluids, resting, and taking acetaminophen might help. Zika can cause microcephaly (a serious birth defect of the brain) and other problems in babies whose mothers were infected while pregnant. The Centers for Disease Control and Prevention recommends that pregnant women do not travel to areas where there is a Zika virus outbreak. If you do decide to travel, first talk to your doctor. You should also be careful to prevent mosquito bites: Use insect repellent Wear clothes that cover your arms, legs, and feet Stay in places that have air conditioning or that use window and door screens Centers for Disease Control and Prevention

MalaCards based summary : Zika Fever, also known as zika virus infection, is related to dengue disease and bacterial conjunctivitis, and has symptoms including fever, rash and headaches. An important gene associated with Zika Fever is PRNT (Prion Locus LncRNA, Testis Expressed). The drugs Contraceptive Agents and Nonoxynol have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and eye.

Disease Ontology : 12 A viral infectious disease that has material basis in Zika virus, which is transmitted by Aedes aegypti mosquitoes and targets neural progenitor cells and neuronal cells in all stages of maturity and has symptom fever, has symptom rash, has symptom headaches and has symptom joint pain.

NIH Rare Diseases : 52 Zika virus infection is spread to people primarily through the bite of an infected mosquito. Zika virus can also be spread from a pregnant mother to her child and through sexual contact with an affected partner. Cases of Zika virus transmission via blood transfusion have also been reported. Zika virus outbreaks are currently occurring in many countries. The illness associated with Zika virus infection is usually mild, with symptoms lasting for several days to a week. The most common symptoms of Zika are fever, rash, joint pain, and conjunctivitis (red eyes). However, research has suggested an association between Zika virus infection and Guillain-Barre syndrome (GBS) in a small percentage of cases. Zika virus infection during pregnancy can cause adverse pregnancy outcomes, including microcephaly and other serious brain defects. The full range of health problems associated with Zika virus infection during pregnancy is currently being studied. No vaccine currently exists to prevent Zika virus infection, but there are still ways to protect oneself. The CDC recommends that pregnant women consider postponing travel to Zika-affected areas. People living in or traveling to areas where Zika virus is found should take steps to prevent mosquito bites . Those who have traveled to Zika-affected areas may wish to take steps to prevent sexual transmission of the Zika virus.

CDC : 3 Zika is spread mostly by the bite of an infected Aedes species mosquito (Ae. aegypti and Ae. albopictus). These mosquitoes bite during the day and night. Zika can be passed from a pregnant woman to her fetus. Infection during pregnancy can cause certain birth defects. There is no vaccine or medicine for Zika.

Wikipedia : 74 Zika virus (ZIKV) is a member of the virus family Flaviviridae. It is spread by daytime-active Aedes... more...

Related Diseases for Zika Fever

Diseases related to Zika Fever via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 310)
# Related Disease Score Top Affiliating Genes
1 dengue disease 31.1 PRNT ERVW-1 CD40LG
2 bacterial conjunctivitis 30.5 CNIH1 CD40LG
3 asymptomatic dengue 30.5 PRNT CD40LG
4 dengue shock syndrome 30.1 ERVW-1 CD40LG
5 ebola hemorrhagic fever 30.1 ERVW-1 CD40LG
6 st. louis encephalitis 30.0 PRNT ERVW-1 CD40LG
7 west nile fever 30.0 PRNT ERVW-1 CD40LG
8 viral infectious disease 29.9 STAT2 ERVW-1 CD40LG
9 zika virus congenital syndrome 12.8
10 torch syndrome 11.3
11 hydrocephalus, congenital, 1 10.7
12 encephalitis 10.7
13 alkuraya-kucinskas syndrome 10.5
14 congenital amyoplasia 10.5
15 toxoplasmosis 10.4
16 hydrocephalus 10.4
17 syphilis 10.4
18 tick-borne encephalitis 10.4
19 measles 10.4
20 lissencephaly 10.4
21 glioblastoma multiforme 10.4
22 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 10.3
23 neuroblastoma 10.3
24 stomatitis 10.3
25 autoimmune disease 10.3
26 cerebellar hypoplasia 10.3
27 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.3
28 infertility 10.3
29 acute disseminated encephalomyelitis 10.3
30 transverse myelitis 10.3
31 monkeypox 10.3 PRNT CD40LG
32 kyasanur forest disease 10.3 ERVW-1 CD40LG
33 western equine encephalitis 10.3 PRNT CD40LG
34 neural tube defects 10.3
35 demyelinating polyneuropathy 10.3
36 placenta disease 10.3
37 cytokine deficiency 10.3
38 hepatitis c virus 10.2
39 polymicrogyria with or without vascular-type ehlers-danlos syndrome 10.2
40 primary microcephaly 10.2
41 male infertility 10.2
42 cerebral palsy 10.2
43 purpura 10.2
44 polymicrogyria 10.2
45 pachygyria 10.2
46 kunjin encephalitis 10.2 STAT2 CD40LG
47 meningoencephalitis 10.2
48 thrombocytopenia 10.2
49 yemenite deaf-blind hypopigmentation syndrome 10.2
50 sensorineural hearing loss 10.2

Graphical network of the top 20 diseases related to Zika Fever:



Diseases related to Zika Fever

Symptoms & Phenotypes for Zika Fever

Symptoms:

12
  • fever
  • rash
  • headaches
  • joint pain

Drugs & Therapeutics for Zika Fever

Drugs for Zika Fever (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 17)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Contraceptive Agents Phase 3
2 Nonoxynol Phase 3
3 Spermatocidal Agents Phase 3
4 Contraceptive Agents, Male Phase 3
5 Vaccines Phase 2
6 Immunologic Factors Phase 2
7
Aluminum sulfate Approved Phase 1 10043-01-3
8
Aluminum hydroxide Approved, Investigational Phase 1 21645-51-2
9 Immunoglobulin G Phase 1
10 Rho(D) Immune Globulin Phase 1
11 gamma-Globulins Phase 1
12 Immunoglobulins, Intravenous Phase 1
13 Antibodies, Blocking Phase 1
14 Antibodies Phase 1
15 Immunoglobulins Phase 1
16 Antibodies, Monoclonal Phase 1
17 Pharmaceutical Solutions Phase 1

Interventional clinical trials:

(show top 50) (show all 61)
# Name Status NCT ID Phase Drugs
1 Randomized, Double-Blind, Controlled, Parallel Group Study With the INTERCEPT Blood System for RBCs in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections and Treatment Use Open-Label Extension Study Recruiting NCT03037164 Phase 3
2 VRC 705: A Phase 2/2B, Randomized Trial to Evaluate the Safety, Immunogenicity and Efficacy of a Zika Virus DNA Vaccine in Healthy Adults and Adolescents Active, not recruiting NCT03110770 Phase 2
3 A Phase 1, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Immunogenicity of mRNA 1325 Zika Vaccine in Healthy Adults in a Non-endemic Zika Region Completed NCT03014089 Phase 1
4 A Phase 1, Randomized, Double-Blind Placebo-Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of an Accelerated Vaccination Schedule With a Zika Virus Purified Inactivated Vaccine Plus Alum Adjuvant in Healthy Adults Completed NCT02937233 Phase 1
5 VRC 320: A Phase I, Randomized Clinical Trial to Evaluate the Safety and Immunogenicity of a Zika Virus DNA Vaccine, VRC-ZKADNA090-00-VP, Administered Via Needle and Syringe or Needle-free Injector, PharmaJet, in Healthy Adults Completed NCT02996461 Phase 1
6 Safety and Pharmacokinetic Evaluation of Zika Virus Immune Globulin in Healthy Volunteers Completed NCT03624946 Phase 1
7 A Randomized, Placebo-controlled, Observer-blinded Phase 1 Study to Assess the Safety and Immunogenicity of Two Different Dose Levels of an Alum Adjuvanted Inactivated Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Flavivirus-naïve Adults Aged 18 to 49 Years Completed NCT03425149 Phase 1
8 Phase I, Open-label, Dose-Ranging Study to Evaluate the Safety, Tolerability, and Immunogenicity of GLS-5700 Administered ID Followed by EP in Dengue Virus-Naïve Adults Completed NCT02809443 Phase 1
9 Double Blinded, Randomized, Placebo Controlled, Dose Finding Trial to Evaluate the Optimal Dose of MV-ZIKA, a New Vaccine Against Zika Virus, in Regard to Immunogenicity, Safety, and Tolerability in Healthy Volunteers Completed NCT02996890 Phase 1
10 Phase I, Placebo-Controlled, Double-Blind Study To Evaluate The Safety, Tolerability, AND Immunogenicity Of GLS-5700, Administered ID Followed By Electroporation In Dengue Virus-Seropositive Adults Completed NCT02887482 Phase 1
11 Phase I Evaluation of the Safety and Immunogenicity of the Live Attenuated Zika Vaccine rZIKV/D4Δ30-713 in Flavivirus-naïve Adults Completed NCT03611946 Phase 1
12 Phase 1 First in Human, Time Lagged, Parallel-Group, Single Ascending Dose Study of Tyzivumab in Healthy Adult Volunteers Completed NCT03443830 Phase 1 Tyzivumab
13 VRC 319: A Phase I/Ib, Randomized Clinical Trial to Evaluate the Safety and Immunogenicity of A Zika Virus DNA Vaccine, VRC-ZKADNA085-00-VP, in Healthy Adults Completed NCT02840487 Phase 1
14 Phase 1, Double-blinded, Placebo-Controlled Study of the Safety and Immunogenicity of Alum Adjuvanted Zika Virus Purified Inactivated Vaccine (ZPIV) Administered by the Intramuscular Route in Flavivirus Naïve Adult Subjects Completed NCT02952833 Phase 1 Saline
15 A Phase 1, First-in-Human, Double-blinded, Randomized, Placebo-controlled Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of an Alum Adjuvanted Zika Virus Purified Inactivated Vaccine (ZPIV) in Healthy Flavivirus-Naïve and Flavivirus-Primed Subjects Completed NCT02963909 Phase 1
16 Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study in Healthy Volunteers to Evaluate the Safety and Immunogenicity of AGS-v, a Universal Mosquito-Borne Disease Vaccine Completed NCT03055000 Phase 1
17 Phase 1 First-in-Human, Time Lagged, Single Ascending Dose Study of TY014 in Healthy Adult Volunteers (Safety Arm - 1A) and Sequential Time Lagged, Parallel-Group, Randomised, Placebo-Controlled, Double-Blind, Single Ascending Dose Study of TY014 in YF-17D Vaccine Strain-Challenged Healthy Adult Volunteers (Efficacy Arm - 1B) Completed NCT03776786 Phase 1
18 A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Healthy Flavivirus Seropositive and Seronegative Adults Recruiting NCT04064905 Phase 1
19 Observer Blinded, Randomized Trial to Evaluate Safety and Immunogenicity of a Novel Vaccine Formulation MV-ZIKA-RSP Recruiting NCT04033068 Phase 1
20 Phase 1 Time Lagged, Parallel-Group, Randomized, Placebo-Controlled, Single-Blind, Single Ascending Dose Study of Tyzivumab in ZIKV Infected Patients Recruiting NCT03776695 Phase 1
21 Phase I, Randomized, Double-blinded, Placebo-Controlled Dose De-escalation Study to Evaluate the Safety and Immunogenicity of Alum Adjuvanted Zika Virus Purified Inactivated Vaccine (ZPIV) Administered by the Intramuscular Route in Adult Subjects Who Reside in a Flavivirus Endemic Area Recruiting NCT03008122 Phase 1
22 A Phase I Study to Determine the Safety and Immunogenicity of the Candidate Zika Virus (ZIKV) Vaccine ChAdOx1 Zika in Healthy Adult Volunteers Given as a Standalone Vaccine or Co-administered With the Chikungunya Virus (CHIKV) Candidate Vaccine ChAdOx1 Chik Recruiting NCT04015648 Phase 1
23 A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Safety, Immunogenicity, and Dose Ranging Study of Purified Inactivated Zika Virus Vaccine (PIZV) Candidate in Flavivirus Naïve and Primed Healthy Adults Aged 18 to 49 Years Active, not recruiting NCT03343626 Phase 1 Placebo
24 Études Observationnelles Des conséquences néonatales et pédiatriques de l'Infection à Virus Zika au Cours de la Grossesse Pendant l'épidémie Des départements français d'Amérique de l'année 2016 Unknown status NCT02810210
25 Études Observationnelles Des conséquences de l'Infection à Virus Zika au Cours de la Grossesse Pendant l'épidémie Des départements français d'Amérique de l'année 2016 Unknown status NCT02916732
26 Effect of a Posture Adapter Use on Body Alignment in Standing Position on Children Between 12 and 24 Months Old With Zyka Virys Congenital Syndrome Unknown status NCT03227601
27 Prospective Surveillance and Case Definition Study of Zika Virus Disease and Infection in Adolescents and Adults in Latin America in Preparation for an Efficacy Trial of a Zika Virus Whole Virion, Purified Inactivated Vaccine Completed NCT03158233
28 The Evaluation of Potential Zika, Chikungunya, and Dengue Infections in Mexico (Zik01) Completed NCT02831699
29 Evaluation of the Clinical Performance of the ZIKV Detect™ 2.0 IgM Capture ELISA Completed NCT03776903
30 Sensorimotor Outcomes of Children Exposed to Foetal Zika Virus Infection During the First or Second Trimester of Gestation. Completed NCT03679728
31 Understanding Excretion and Infectivity of Zika Virus in Semen During and After Infection Completed NCT02979938
32 Rash Accompanied by Three or More Dengue-like Symptoms During Pregnancy and Microcephaly: Case-control Study Completed NCT02741882
33 Study of Zika Virus and Related Arbovirus Infections in Deferred Blood Donors Completed NCT02794181
34 Efficacy of Aquatic Physiotherapy in Stress Level and Muscle Tone of Children Between 3 and 24 Months With Microcephaly by Zika Virus Congenital Syndrome Completed NCT03330600
35 Pilot Study to Detect Zika Virus in Sperm Completed NCT02874456
36 Randomized Trial to Assess Parental Response to Different Presentations of Vaccination Data for Schools and Child Care Centers Completed NCT02957344
37 TRMC-Bio "Molecular Profiling of Gut Microbiome, Microbiome Metabolome, Serum Chemistry, and Metabolism-Associated SNPs in Elite Athletes" Completed NCT02818413
38 Spatial Repellent Products for Control of Vector-borne Diseases - Dengue Completed NCT03553277
39 Pilot Study to Detect DENGUE Virus in Sperm. Completed NCT03612609
40 Estimated Cumulative Incidence of Zika Infection at the End of the First Epidemic in the French West Indies in a Sample of Patients Followed for HIV Infection. Recruiting NCT03161444
41 Risk Evaluation of Fetal Nervous System and Neurodevelopment Disorders in Infants of Women Exposed to Zika Virus Infection During Pregnancy Recruiting NCT02943304
42 Descriptive and Prognostic Study of Arbovirus Infections in France, Based on a Hospital Cohort of Children and Adults With Suspected Arbovirose.r Recruiting NCT01099852
43 Children (CH) Cohort for the Evaluation of Developmental and Neurological Abnormalities in Infants Born to Mothers Residing in Areas With Zika Virus Transmission During Pregnancy Recruiting NCT03393286
44 World Mosquito Program - Colombia (WMP-COLOMBIA): The Impact of City-wide Deployment of Wolbachia-infected Mosquitoes on Arboviral Disease Incidence in Medellin and Bello, Colombia Recruiting NCT03631719
45 Vertical Exposure to Zika Virus and Its Consequences for Child Neurodevelopment: Cohort Study in Fiocruz/IFF Recruiting NCT03255369
46 Applying Wolbachia to Eliminate Dengue (AWED): A Non-blinded Cluster Randomised Controlled Trial to Assess the Efficacy of Wolbachia-infected Mosquito Deployments to Reduce Dengue Incidence in Yogyakarta, Indonesia Recruiting NCT03055585
47 Neurovirus Emerging in the Americas Study (NEAS): Neurologic Manifestations of the Arbovirus Dengue, Chikungunya and Zika Infections in Colombia Recruiting NCT03206541
48 The International Cohort Study of Children Born to Women Infected With Zika Virus During Pregnancy Recruiting NCT04118738
49 Clinical Evaluation of the FilmArray® Global Fever (GF) Panel Recruiting NCT02968355
50 Surveillance of Zika-related Microcephaly in Sub-Saharan Africa and Asia Recruiting NCT03922594

Search NIH Clinical Center for Zika Fever

Cochrane evidence based reviews: zika virus infection

Genetic Tests for Zika Fever

Anatomical Context for Zika Fever

MalaCards organs/tissues related to Zika Fever:

40
Brain, Testes, Eye, T Cells, Placenta, Fetal Brain, Whole Blood

Publications for Zika Fever

Articles related to Zika Fever:

(show top 50) (show all 1325)
# Title Authors PMID Year
1
Characteristics of Zika virus infection among international travelers: A prospective study from a Spanish referral unit. 42 61
31805400 2019
2
Long-term protection of rhesus macaques from Zika virus reinfection. 42
31801867 2019
3
Design, synthesis and discovery of novel N,N'-carbazoyl-aryl-urea inhibitors of Zika NS5 methyltransferase and virus replication. 42
31805205 2019
4
Lineage-dependent differences of Zika virus infection in a susceptible mouse model are associated with different profiles of cytokines, chemokines, growth factors and acute phase proteins. 61
31577989 2020
5
Cost-effectiveness of Prophylactic Zika Virus Vaccine in the Americas. 61
31742512 2019
6
A preliminary survey of ZIKA virus infection by nucleic acid test in the volunteer blood donor samples in Shenzhen China. 61
31829444 2019
7
Zika virus infection in pregnancy and infant growth, body composition in the first three months of life: a cohort study. 61
31844129 2019
8
Zika Vaccine Development: Current Status. 61
31806107 2019
9
Viral Infections and the Neonatal Brain. 61
31813517 2019
10
Zika virus infection: A correlation between prenatal ultrasonographic and postmortem neuropathologic changes. 61
31710135 2019
11
Evolution of the innate and adaptive immune response in women with acute Zika virus infection. 61
31792427 2019
12
Seroprevalence of Zika virus in selected regions in Kenya. 61
31639184 2019
13
Antiviral activity of the FDA-approved drug candesartan cilexetil against Zika virus infection. 61
31669333 2019
14
Zika virus: A possible emerging threat for Bangladesh! 61
31819889 2019
15
Isolation of Mayaro Virus from a Venezuelan Patient with Febrile Illness, Arthralgias, and Rash: Further Evidence of Regional Strain Circulation and Possible Long-Term Endemicity. 61
31595869 2019
16
Innate immune response in patients with acute Zika virus infection. 61
30879197 2019
17
Central and peripheral nervous system involvement in Zika virus infection in a child. 61
31222674 2019
18
Maternal Zika Virus Infection: Association With Small-for-Gestational-Age Neonates and Preterm Birth. 61
31764729 2019
19
Zika Virus Infection In The Developing Mouse Produces Dramatically Different Neuropathology Dependent On Viral Strain. 61
31836659 2019
20
Suppression of Zika Virus Infection in the Brain by the Antiretroviral Drug Rilpivirine. 61
31653397 2019
21
Zika Virus Infection, Reproductive Organ Targeting, and Semen Transmission in the Male Olive Baboon. 61
31597777 2019
22
Zika virus noncoding sfRNAs sequester multiple host-derived RNA-binding proteins and modulate mRNA decay and splicing during infection. 61
31519749 2019
23
Capsid containing virus like particle vaccine against Zika virus made from a stable cell line. 61
31607605 2019
24
Genetic diversity of Collaborative Cross mice controls viral replication, clinical severity and brain pathology induced by Zika virus infection, independently of Oas1b. 61
31694939 2019
25
Preventing Sexual Transmission of Zika Virus Infection during Pregnancy, Puerto Rico, USA, 20161. 61
31625850 2019
26
Health outcomes associated with Zika virus infection in humans: a systematic review of systematic reviews. 61
31685512 2019
27
Maternal Zika Virus Infection: Association With Small-for-Gestational-Age Neonates and Preterm Birth. 61
31698388 2019
28
Design, synthesis and discovery of andrographolide derivatives against Zika virus infection. 61
31838328 2019
29
Fatal Zika virus infection in the Americas: A systematic review. 61
31499212 2019
30
Impact of weather seasonality and sexual transmission on the spread of Zika fever. 61
31745123 2019
31
Zika virus infection in India. 61
31693151 2019
32
Subclinical in utero Zika virus infection is associated with interferon alpha sequelae and sex-specific molecular brain pathology in asymptomatic porcine offspring. 61
31725819 2019
33
Erythromycin Estolate Inhibits Zika Virus Infection by Blocking Viral Entry as a Viral Inactivator. 61
31731598 2019
34
Diaphragmatic paralysis: Evaluation in infants with congenital Zika syndrome. 61
31595718 2019
35
Oligomeric state of the ZIKV E protein defines protective immune responses. 61
31601808 2019
36
Emergence of the Asian lineage of Zika virus in Angola: an outbreak investigation. 61
31559967 2019
37
Low seroprevalence of Zika virus infection among adults in Southern Taiwan. 61
31646973 2019
38
Acute Zika virus infection in an asymptomatic blood donor at the onset of the Puerto Rico epidemic. 61
31407817 2019
39
Zika Virus Infection Induces DNA Damage Response in Human Neural Progenitors That Enhances Viral Replication. 61
31375586 2019
40
Zika virus infection: an update. 61
31158508 2019
41
Zika virus infection in pregnancy: Establishing a case definition for clinical research on pregnant women with rash in an active transmission setting. 61
31589611 2019
42
Drugs for the Treatment of Zika Virus Infection. 61
31549836 2019
43
Zika Virus Infection - After the Pandemic. 61
31597021 2019
44
Palmatine inhibits Zika virus infection by disrupting virus binding, entry, and stability. 61
31472967 2019
45
Optimization of 1,3-disubstituted urea-based inhibitors of Zika virus infection. 61
31477351 2019
46
Identifying high risk areas of Zika virus infection by meteorological factors in Colombia. 61
31651247 2019
47
The small GTPase RAB1B promotes antiviral innate immunity by interacting with TNF receptor-associated factor 3 (TRAF3). 61
31375559 2019
48
Receptive language skills among young children in rural Guatemala: The relationship between the Test de Vocabulario en Imagenes Peabody and a translated and adapted version of the Mullen Scales of Early Learning. 61
31270836 2019
49
Linking nutrient stoichiometry to Zika virus transmission in a mosquito. 61
31227906 2019
50
Management of Patients in the Context of Zika Virus: ACOG COMMITTEE OPINION SUMMARY, Number 784. 61
31441819 2019

Variations for Zika Fever

Expression for Zika Fever

Search GEO for disease gene expression data for Zika Fever.

Pathways for Zika Fever

GO Terms for Zika Fever

Biological processes related to Zika Fever according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 platelet activation GO:0030168 8.8 FGA CD40LG AXL

Sources for Zika Fever

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....